Found 3 articles for: "Tildrakizumab"
Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness a...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report
October 2021 | Volume 20 | Issue 10 | Case Reports | 1117 | Copyright © October 2021
Palmoplantar pustulosis (PPP) is a rare, recurrent skin disorder that presents a major challenge to clinical therapy. We report a case of a 69-year-old woman with a 20-year history of psoriasis with s...
Read More
